Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02PPN
|
|||
| Former ID |
DAP000024
|
|||
| Drug Name |
Methylphenidate
|
|||
| Synonyms |
Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Approved | [1], [2] | |
| Traumatic brain injury [ICD-11: NA07.Z] | Phase 4 | [1], [3] | ||
| Therapeutic Class |
Central Nervous System Stimulants
|
|||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H19NO2
|
|||
| Canonical SMILES |
COC(=O)C(C1CCCCN1)C2=CC=CC=C2
|
|||
| InChI |
1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
|
|||
| InChIKey |
DUGOZIWVEXMGBE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 113-45-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9405, 5336253, 7979945, 8152600, 10504398, 14798219, 26746622, 29223265, 46505929, 47206727, 48416258, 49854760, 53789341, 57322165, 78286794, 85209963, 103209574, 103858000, 103958410, 104305599, 124954808, 127787857, 134337354, 134974024, 135709935, 136897384, 137007933, 142361369, 160963768, 163411030, 178103810, 179148478, 216106193, 223897828, 226423048, 249807024, 249948308, 252404612
|
|||
| ChEBI ID |
CHEBI:84276
|
|||
| ADReCS Drug ID | BADD_D01431 ; BADD_D01432 | |||
| SuperDrug ATC ID |
N06BA04
|
|||
| SuperDrug CAS ID |
cas=000113451
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methylphenidate can be metabolized by Bifidobacterium ruminantium (log2FC = -0.373; p = 0.042). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta ATCC 25559
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methylphenidate can be metabolized by Eggerthella lenta ATCC 25559 (log2FC = -0.433; p = 0.012). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methylphenidate can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.451; p = 0.006). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methylphenidate can be metabolized by Clostridium sp. (log2FC = -0.538; p = 0.006). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine transporter (DAT) | Target Info | Blocker | [5] |
| KEGG Pathway | Dopaminergic synapse | |||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Dopaminergic Neurogenesis | ||||
| Parkinsons Disease Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Neurotransmitter Clearance In The Synaptic Cleft | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7236). | |||
| REF 2 | Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. | |||
| REF 3 | Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36. | |||
| REF 4 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 5 | Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.